文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

危重急性肾损伤患者肾脏替代治疗模式的比较:系统评价与网状Meta分析

Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Crit Care Explor · 2021-05-12
一句话结论网状Meta分析提示:危重AKI患者中连续肾脏替代治疗与间断血液透析死亡率无差异,但连续肾脏替代治疗可能增加肾脏恢复;所有结论基于极低至中等确定性证据。

该系统评价与网状Meta分析纳入30项随机对照试验(n=3,774例)的危重急性肾损伤成人患者,比较连续肾脏替代治疗、间断血液透析、缓慢低效延长透析和腹膜透析四种模式(主分析四节点,次要分析九节点)。主要结果显示连续肾脏替代治疗与间断血液透析死亡率无差异(RR 1.04,95%CI 0.93-1.18,低确定性),连续肾脏替代治疗相比缓慢低效延长透析(RR 1.06,95%CI 0.85-1.33,低确定性)和腹膜透析(RR 1.16,95%CI 0.92-1.49,低确定性)可能死亡率增加。连续肾脏替代治疗相比间断血液透析可能增加肾脏恢复(RR 1.15,95%CI 0.91-1.45,低确定性),但两者相比缓慢低效延长透析和腹膜透析肾脏恢复可能更差(低确定性)。腹膜透析可能肾脏支持时间最短和ICU住院时间最短(多数比较低确定性),缓慢低效延长透析可能住院时间最短(所有比较低或中等确定性)和机械通气天数最短(所有比较低确定性)。连续肾脏替代治疗与间断血液透析低血压无差异(RR 0.92,95%CI 0.72-1.16,中等确定性),但两者相比腹膜透析低血压和出血风险增加(低或中等确定性)。作者结论:上述模式间差异可能很小,任何模式都是危重患者的合理选择。

要点

  • 连续肾脏替代治疗与间断血液透析死亡率无差异(RR 1.04,95%CI 0.93-1.18,低确定性),临床选择两者均可。
  • 连续肾脏替代治疗相比缓慢低效延长透析(RR 1.06,95%CI 0.85-1.33)和腹膜透析(RR 1.16,95%CI 0.92-1.49)可能死亡率增加,均为低确定性。
  • 连续肾脏替代治疗相比间断血液透析可能增加肾脏恢复(RR 1.15,95%CI 0.91-1.45,低确定性),但两者相比缓慢低效延长透析和腹膜透析肾脏恢复可能更差(低确定性)。
  • 腹膜透析可能肾脏支持时间和ICU住院时间最短(多数比较低确定性);缓慢低效延长透析可能住院时间和机械通气天数最短(低或中等确定性)。
  • 连续肾脏替代治疗与间断血液透析低血压无差异(RR 0.92,95%CI 0.72-1.16,中等确定性),但两者相比腹膜透析低血压和出血风险增加(低或中等确定性)。

适用人群与场景

  • 危重成人急性肾损伤患者,纳入比较不同肾脏替代治疗模式疗效与安全性的随机对照试验。

研究设计与关键结果

  • 研究类型:系统评价与网状Meta分析,纳入30项随机对照试验(n=3,774例患者)。
  • 主要分析为四节点分析:连续肾脏替代治疗、间断血液透析、缓慢低效延长透析和腹膜透析;次要分析细分为九节点。
  • 连续肾脏替代治疗与间断血液透析死亡率无差异(RR 1.04,95%CI 0.93-1.18,低确定性);连续肾脏替代治疗相比缓慢低效延长透析(RR 1.06,95%CI 0.85-1.33,低确定性)和腹膜透析(RR 1.16,95%CI 0.92-1.49,低确定性)可能死亡率增加。
  • 连续肾脏替代治疗相比间断血液透析可能增加肾脏恢复(RR 1.15,95%CI 0.91-1.45,低确定性);连续肾脏替代治疗和间断血液透析相比缓慢低效延长透析和腹膜透析肾脏恢复可能更差(低确定性)。
  • 腹膜透析可能肾脏支持时间最短和ICU住院时间最短(多数比较低确定性);缓慢低效延长透析可能住院时间最短(所有比较低或中等确定性)和机械通气天数最短(所有比较低确定性)。
  • 连续肾脏替代治疗与间断血液透析低血压无差异(RR 0.92,95%CI 0.72-1.16,中等确定性);两者相比腹膜透析低血压和出血风险增加(低或中等确定性)。
  • 缓慢低效延长透析的并发症报告不充分,无法用于比较。
  • 作者结论:缓慢低效延长透析联合血液滤过可能是降低死亡率最有效的干预;腹膜透析疗效好且并发症最少,但可能并非在所有环境中可行。

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析,使用GRADE方法评估证据确定性。
  • 所有结论基于极低至中等确定性证据,受不精确性限制。

对床旁实践的改变

  • 作者认为,ICU临床医生应放心,连续肾脏替代治疗、间断血液透析、缓慢低效延长透析以及在临床适当时腹膜透析之间的差异可能很小,任何这些模式都是危重患者的合理选择。
  • 缓慢低效延长透析联合血液滤过可能是降低死亡率最有效的干预(基于低确定性证据)。
  • 腹膜透析疗效好且并发症最少,但可能并非在所有环境中可行。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To compare different modalities of renal replacement therapy in critically ill adults with acute kidney injury.

DATA SOURCES: We searched Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to 25 May, 2020. We included randomized controlled trials comparing the efficacy and safety of different renal replacement therapy modalities in critically ill patients with acute kidney injury.

STUDY SELECTION: Ten reviewers (working in pairs) independently screened studies for eligibility, extracted data, and assessed risk of bias.

DATA EXTRACTION: We performed random-effects frequentist network meta-analyses and used the Grading of Recommendations, Assessment, Development, and Evaluation approach to assess certainty of evidence. The primary analysis was a four-node analysis: continuous renal replacement therapy, intermittent hemodialysis, slow efficiency extended dialysis, and peritoneal dialysis. The secondary analysis subdivided these four nodes into nine nodes including continuous veno-venous hemofiltration, continuous veno-venous hemodialysis, continuous veno-venous hemodiafiltration, continuous arterio-venous hemodiafiltration, intermittent hemodialysis, intermittent hemodialysis with hemofiltration, slow efficiency extended dialysis, slow efficiency extended dialysis with hemofiltration, and peritoneal dialysis. We set the minimal important difference threshold for mortality as 2.5% (relative difference, 0.04).

DATA SYNTHESIS: Thirty randomized controlled trials (n = 3,774 patients) proved eligible. There may be no difference in mortality between continuous renal replacement therapy and intermittent hemodialysis (relative risk, 1.04; 95% CI, 0.93-1.18; low certainty), whereas continuous renal replacement therapy demonstrated a possible increase in mortality compared with slow efficiency extended dialysis (relative risk, 1.06; 95% CI, 0.85-1.33; low certainty) and peritoneal dialysis (relative risk, 1.16; 95% CI, 0.92-1.49; low certainty). Continuous renal replacement therapy may increase renal recovery compared with intermittent hemodialysis (relative risk, 1.15; 95% CI, 0.91-1.45; low certainty), whereas both continuous renal replacement therapy and intermittent hemodialysis may be worse for renal recovery compared with slow efficiency extended dialysis and peritoneal dialysis (low certainty). Peritoneal dialysis was probably associated with the shortest duration of renal support and length of ICU stay compared with other interventions (low certainty for most comparisons). Slow efficiency extended dialysis may be associated with shortest length of hospital stay (low or moderate certainty for all comparisons) and days of mechanical ventilation (low certainty for all comparisons) compared with other interventions. There was no difference between continuous renal replacement therapy and intermittent hemodialysis in terms of hypotension (relative risk, 0.92; 95% CI, 0.72-1.16; moderate certainty) or other complications of therapy, but an increased risk of hypotension and bleeding was seen with both modalities compared with peritoneal dialysis (low or moderate certainty). Complications of slow efficiency extended dialysis were not sufficiently reported to inform comparisons.

CONCLUSIONS: The results of this network meta-analysis suggest there is no difference in mortality between continuous renal replacement therapy and intermittent hemodialysis although continuous renal replacement therapy may increases renal recovery compared with intermittent hemodialysis. Slow efficiency extended dialysis with hemofiltration may be the most effective intervention at reducing mortality. Peritoneal dialysis is associated with good efficacy, and the least number of complications however may not be practical in all settings. Importantly, all conclusions are based on very low to moderate certainty evidence, limited by imprecision. At the very least, ICU clinicians should feel comfortable that the differences between continuous renal replacement therapy, intermittent hemodialysis, slow efficiency extended dialysis, and, where clinically appropriate, peritoneal dialysis are likely small, and any of these modalities is a reasonable option to employ in critically ill patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Ye Z, Wang Y, Ge L, et al. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021. PMID: 34079944. doi:10.1097/CCE.0000000000000399

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。